70384-29-1Cc1c(N)nc(C(CC(N)=O)NCC(N)C(N)=O)nc1C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCc1nc(-c2nc(C(=O)NCCCNC(C)c3ccccc3)cs2)cs1)C(C)O)C(OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1cnc[nH]1.O=S(=O)(O)OZHHIHQFAUZZMTG-UHFFFAOYSA-N70384-29-1CHEMBL1994483Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
DescriptionPeplomycin was derived biosynthetically from Streptomyces verticillus, the bleomycinproducing organism, in the course of efforts to obtain bleomycin derivatives with high activity and low toxicity. This antibiotic was found by Nippon Kayaku Co. and the Institute of Microbial Chemistry, Japan, in 1974. Its anticancer effects appear earlier than those of bleomycin; consequently, the period of therapy is shortened. Peplomycin is also active against metastatic cancer of the lymph nodes and shows less pneumotoxicity than bleomycin.
UsesA derivative of Bleomycin with cytostatic activity and less pulmonary toxicity than the natural Bleomycin mixture.
No reaction records under the current filter.
Loading…